血清巨噬细胞抑制因子-1在胰腺癌临床检测诊断中的应用价值  

Value of macrophage inhibitory cytokine-1 as a novel marker for detecting and diagnosing pancreatic cancer

作　　者：邵长君[1] 王小兵[1] 汪毅[2] 李茉[1] 田海梅[1] 单毅[2] 赵平[2] 张伟[1] 

机构地区：[1]中国协和医科大学中国医学科学院肿瘤医院肿瘤研究所生物检测中心,北京市100021 [2]中国协和医科大学中国医学科学院肿瘤医院腹部外科,北京市100021

出　　处：《世界华人消化杂志》2007年第34期3644-3648,共5页World Chinese Journal of Digestology

基　　金：国家十五攻关资助项目;No.2004BA703B11;国家高技术研究发展计划(863计划)资助项目;No.2007AA02Z485~~

摘　　要：目的:探讨MIC-1作为新的肿瘤标志物在胰腺癌临床血清学诊断中的应用价值.方法:采用酶联免疫方法检测101例胰腺癌、10例胰腺良性病变患者及50例正常人血清中的MIC-1表达水平,并与肿瘤标记物CA199进行比较.结果:胰腺癌患者血清中MIC-1表达水平(1427±1056 ng/L)显著高于胰腺良性肿瘤(362±177 ng/L)和正常人血清水平(299±159 ng/L)(P<0.001).MIC-1检测胰腺癌的敏感性、特异性、阳性预测值、阴性预测值和AUC分别为81.2%、94%、96.5%、71.2%和0.92.分别高于CA199的相应对应值72.4%、89.6%、93.4%、61.4%和0.86.与CA199联合检测时,敏感性可提高至91.1%.结论:MIC-1有可能成为用于胰腺癌临床诊断的新肿瘤标记物.AIM： To evaluate the value of serum macrophage inhibitory cytokine-1 （MIC-1） as a novel marker for diagnosing pancreatic cancer. METHODS： Serum MIC-1 levels were measured by sandwich ELISA assay in 101 patients with pancreatic adenocarcinomas, 10 patients with benign pancreatic tumors, and 50 healthy control subjects. The diagnostic performance of se-rum MIC-1 as a marker of pancreatic cancer was compared with that of serum CA199. RESULTS： MIC-1 levels were significantly higher in patients with pancreatic adenocarcinoma than in those with benign pancreatic neoplasms or in healthy controls （1427±1056 ng/L vs 362±177 ng/L, 299±159 ng/L）. The diagnostic accuracy of MIC-1 （sensitivity 81.2%, specificity 94%, positive predictive value 96.5%, negative predic- tive value 71.2%; AUC 0.92） at detecting pancreatic adenocarcinomas was higher than that of CA199 （sensitivity, 72.4% specificity 89.6%, positive predictive value 93.4%, negative predictive value 61.4%; AUC 0.86）, and the combination of MIC-1 and CA199 significantly improved diagnostic sensitivity （91.1 %）. CONCLUSION： MIC-1 mor marker and aid in atic adenocarcinoma.

关 键 词：胰腺癌 巨噬细胞抑制因子 CA199 酶联免疫方法 

分 类 号：R979.5[医药卫生—药品] R575.2[医药卫生—药学]